Main Menu

Radiotherapy Clinical Trials

Open to recruitment

ART DECO: A phase III multi-centre randomised controlled trial to determine the potential of dose escalated IMRT to improve locoregional failure free rate (LRFFR) and laryngeal preservation in patients with locally advanced laryngeal and hypopharyngeal cancers, without increasing the incidence of severe acute and late toxicities to unacceptable levels.

COSTAR: COchlear Sparing Therapy And conventional Radiation - a phase III multi-centre randomised controlled trial designed to demonstrate a difference in the proportion of patients suffering sensori-neural hearing loss of at least 10dB in bone conduction at 4000 Hz.

FAST Forward: Randomised clinical trial testing a 1-week course of curative whole breast radiotherapy against a standard 3-week schedule in terms of local cancer control and late adverse effects in patients with early breast cancer.

IMPORT HIGH: IMPORT HIGH - Randomised trial testing dose escalated intensity modulated radiotherapy (IMRT) for women treated by breast conservation surgery and appropriate systemic therapy for early breast cancer.

PIVOTAL: PIVOTAL - A randomised phase II trial of Prostate and pelvIs versus prOstaTe Alone treatment for Locally advanced prostate cancer. 

PRIMETIME: Post-operative avoidance of radiotherapy: biomarker selection of women categorised to be in a very low risk group by IHC4+C.

In active follow-up

BASO DCIS II: Randomised trial testing observation (no radiotherapy) against radiotherapy in women with low-risk completely excised ER positive ductal carcinoma in situ (DCIS) of the breast on adjuvant endocrine therapy.

CHHiP: Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer

DCIS II: Randomised trial testing observation (no radiotherapy) against radiotherapy in women with low-risk completely excised ER positive ductal carcinoma in situ (DCIS) of the breast on adjuvant endocrine therapy.

FAST: A prospective randomised clinical trial designed to test 5 fractions of 5.7 Gy and 6.0 Gy against 25 fractions of 2.0 Gy in terms of late  normal tissue effects and tumour control in women prescribed whole breast radiotherapy (no boost) after local excision of early breast cancer.

IMPORT LOW: Randomised trial testing intensity modulated and partial organ radiotherapy following breast conservation surgery for early breast cancer.

PARSPORT: PARSPORT is a Phase III multi-centre randomised controlled trial of parotid sparing IMRT in patients with head and neck cancer.

ProSTART: A Pilot Study for a Phase III Clinical Trial in Patients with Favourable Risk Prostate Cancer Comparing Active Surveillance Therapy Against Radical Treatment

SPARE: Randomised trial of Selective bladder Preservation Against Radical Excision (cystectomy) in muscle invasive T2/T3 transitional cell carcinoma of the bladder – feasibility study.

START: The national Standardisation of Radiotherapy (START) Trial in breast cancer was launched in January 1999 and aimed to identify the optimal regimen in terms of tumour control, late normal tissue effects and patient-reported quality of life, and to standardise routine radiotherapy treatments throughout the NHS for women with early breast cancer.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.